Table 1.
Descriptive Characteristics of 58 Consecutive Patients Newly Diagnosed with Oligometastatic Prostate Cancer Between 2012 and 2016
| Variables | MDT Group (n=26) |
Non-MDT Group (n=32) |
P-value |
|---|---|---|---|
| Median (Range) | Median (Range) | ||
| Baseline Characteristics | |||
| Age (years) | 65.5 (54−78) | 67.5 (51–79) | 0.430a |
| Follow-up (months) | 43.1 (15–61) | 47.6 (18–65) | 0.538a |
| Volume of prostate (cc) | 54.4 (36.1–79.3) | 49.8 (29.3–82.6) | 0.486a |
| Serum ALK (IU/L) | 126.2 (27.8–185.6) | 143.8 (35.4–325.7) | 0.876a |
| PSA at diagnosis (ng/mL) | 35.3 (8.9–213.5) | 36.4 (9.7–756.3) | 0.573a |
| n (%) | n (%) | ||
| Positive cores of biopsy | |||
| ≥ 50 % | 14 (53.8 %) | 15 (46.9 %) | 0.792b |
| ≥ 65 % | 15 (57.7 %) | 19 (59.4 %) | >0.9999b |
| Biopsy Gleason grade group | |||
| 1 | 7 (26.9 %) | 10 (31.3 %) | 0.778b |
| 2 | 6 (23.1 %) | 7 (21.9 %) | >0.9999b |
| 3 | 5 (19.2%) | 5 (15.6 %) | 0.740b |
| 4 | 5 (19.2 %) | 6 (18.8%) | >0.9999b |
| 5 | 3 (11.5 %) | 4 (12.5 %) | >0.9999b |
| Number of bone metastases | |||
| 1–3 | 20 (76.9 %) | 22 (68.7 %) | 0.564b |
| 4–5 | 6 (23.1 %) | 10 (31.3 %) | |
| Extrapelvic LNs involvement | 5 (19.2 %) | 4 (12.5 %) | 0.717b |
| PSA nadir (ng/mL) | |||
| <0.05 | 22 (84.6 %) | 18 (56.3 %) | 0.025b |
| <2 | 25 (96.2 %) | 30 (93.8 %) | >0.9999b |
| Clinical TNM stage | |||
| Clinical T stage | |||
| cT1c to 2 | 5 (19.2%) | 5 (15.6 %) | 0.740b |
| cT3a | 13 (50.0 %) | 12 (37.5 %) | 0.427b |
| cT3b to 4 | 8 (30.8 %) | 15 (46.9 %) | 0.283b |
| Radiological N stage | |||
| cN0 | 20 (76.9%) | 21 (65.6 %) | 0.397b |
| cN1 | 6 (23.1 %) | 11 (34.4 %) | |
| Postoperative pathohistology | |||
| Gleason grade group | |||
| 2 | 10 (38.5 %) | 15 (46.9 %) | 0.599b |
| 3 | 6 (23.1 %) | 9 (28.1 %) | 0.767b |
| 4 | 7 (26.9 %) | 3 (9.38 %) | 0.095b |
| 5 | 3 (11.5 %) | 5 (15.6 %) | 0.720b |
| Postoperative T stage | |||
| pT1c to 2 | 2 (7.7 %) | 4 (12.5 %) | 0.681b |
| pT3a | 13 (50.0 %) | 16 (50.0 %) | >0.9999b |
| pT3b to 4 | 11 (42.3 %) | 12 (37.5 %) | 0.790b |
| N stage | |||
| cN0 | 16 (61.5%) | 22 (68.8 %) | 0.591b |
| cN1 | 10 (38.5 %) | 10 (32.2 %) | |
| Positive surgical margins | 3 (11.5 %) | 4 (12.5 %) | >0.9999b |
Notes: aDetermined by unpaired t-test. bDetermined by Fisher’s exact test.
Abbreviations: ALK, alkaline phosphatase; SBRT, stereotactic body radiation therapy; MDT, metastasis-directed therapy; Grade Group 1, Gleason score ≤6; Grade Group 2, Gleason score 3+4=7; Grade Group 3, Gleason score 4+3=7; Grade Group 4, Gleason score 8; Grade Group 5, Gleason scores 9 and 10.